Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 7Recruiting 3Unknown 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Pain 1Neurotoxicity Syndromes 1Hematologic Neoplasms 1

Interventions

Specimen Handling 334Magnetic Resonance Spectroscopy 334Radiotherapy 315Cyclophosphamide 295pembrolizumab 281Cisplatin 267Carboplatin 245Drug Therapy 237Blood Specimen Collection 233Biopsy 204Bevacizumab 186Gemcitabine 178venetoclax 172Radiosurgery 169Capecitabine 164Oxaliplatin 163fludarabine 161Nivolumab 156Paclitaxel 155Standard of Care 136Surveys and Questionnaires 130Surgical Procedures, Operative 130Dexamethasone 126Fluorouracil 124Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104Azacitidine 101atezolizumab 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × OTHER × Duloxetine Hydrochloride × Clear all
NCT04560673 2025-12-31

Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy

M.D. Anderson Cancer Center

Phase 2 Recruiting
380 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT04970121 2024-09-25

Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients with Taxanes-induced Painful Peripheral Neuropathy

The First Affiliated Hospital of Bengbu Medical University

Phase 2 Recruiting
100 enrolled

Pain

NCT06551051 2024-09-19

ADC-induced Neurotoxicity Treated With Duloxetine

Fudan University

Phase 2 Recruiting
37 enrolled

Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡